Onxeo SA announced the appointments of Françoise Bono, PhD, to the role of Chief Scientific Officer and Olivier de Beaumont, MD, MBA, to the role of Chief Medical Officer. Their very specialized expertise will enable the Company to carry out its various projects, notably development activities on AsiDNA™. Previously, Françoise Bono spent over 25 years with Sanofi and Evotec and was, until late 2016, Evotec Executive Vice-President, Oncology. Since 2005, Olivier de Beaumont was with Stallergenes Greer as Senior Vice President, Head of Global Clinical Development, Pharmacovigilance and Medical Affairs, and a member of the Executive Committee.